Tag - ADAG

Developments

Adagene and Incyte collaborate to evaluate combination therapy in MSS CRC patients

Adagene (NASDAQ: ADAG) and Incyte (NASDAQ: INCY) have announced a clinical collaboration to evaluate the combination of muzastotug (ADG126) and INCA33890, a TGFβR2 × PD-1 bispecific antibody, in patients with...

April 2, 2026

Developments

FDA grants fast track designation for Adagene’s muzastotug

Adagene (NASDAQ: ADAG) has announced that the FDA has designated muzastotug, in combination with Merck’s (NYSE: MRK) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), as a fast track product for adult patients with...

December 16, 2025

Developments

Adagene, Exelixis amend license agreement to develop third masked mAb

Adagene (NASDAQ: ADAG) has announced an amendment to the 2021 collaboration and license agreement with Exelixis (Nasdaq: EXEL) to enable the development of a third novel masked monoclonal antibody (mAb) drug conjugate...

September 16, 2025

Executive Moves

Adagene appoints Dr. Axel Hoos as executive advisor

Adagene (NASDAQ: ADAG) has announced the appointment of immuno-oncology pioneer, Axel Hoos, MD, PhD, as executive advisor. Most recently, Dr. Hoos served as CEO of Scorpion Therapeutics, which was acquired by Eli Lilly...

September 3, 2025

Tag - ADAG

Adagene and Incyte collaborate to evaluate combination therapy in MSS CRC patients

FDA grants fast track designation for Adagene’s muzastotug

Adagene, Exelixis amend license agreement to develop third masked mAb

Adagene appoints Dr. Axel Hoos as executive advisor

Subscribe